French Claims Data Tracks Direct Oral Anticoagulant Uptake in Cancer Patients
Direct oral anticoagulants accounted for 32.6% of initial blood-thinning regimens in active cancer patients between 2021 and 2022, rising from 15.3% during the 2016–2018 period, according to an analysis published in JAMA Network Open. The findings track how clinical trial data and updated medical guidelines have translated into routine medical practice across France. While the uptake in cancer-associated venous thromboembolism has grown substantially, prescribing habits diverge sharply depending on tumor type, treatment modality, and the specialty of the physician managing the care.
Clinical Trials Versus Real-World Oncology Prescribing Patterns
Randomized controlled trials, including the Caravaggio study, established that direct oral anticoagulants are noninferior to traditional low-molecular-weight heparins for preventing recurrent blood clots in patients fighting malignancies. National and international medical guidelines subsequently named these medications as a first-line therapy. Despite this evidence, Romain Varnier, MD, and fellow investigators at Université Claude Bernard Lyon noted that shifts in clinical practice do not happen overnight following guideline updates. In patients without active cancer, usage climbed even faster over the same timeframe, jumping from 63.5% to 81.1%. Alok A. Khorana, MD, of the Cleveland Clinic Foundation, told TCTMD that the findings generalize well to the United States, where uptake is likely higher due to patient copay structures for injectable alternatives.
Tumor Types and Treatment Regimens Dictate Anticoagulant Choice
Prescribing data from 683,184 patients in the French National Health Data System reveal that physicians tailor their choices to specific clinical risks. Patients diagnosed with breast, urological, hematological, and skin cancers received direct oral anticoagulants most frequently. Conversely, individuals with gastrointestinal and gynecological cancers were prescribed the drugs less often, driven by clinical concerns over bleeding risks in those specific populations. Patients undergoing systemic anticancer therapies also experienced lower rates of direct oral anticoagulation. The study authors suggest this hesitation stems from worries regarding treatment-related thrombocytopenia during cytotoxic chemotherapy and potential drug-drug interactions with oral oncology agents. Active brain metastases similarly limited usage due to intracranial hemorrhage fears and the exclusion of such patients from pivotal randomized trials.
General Practitioners Outpace Specialists in Initial Therapy
By provider type, general practitioners proved more likely to initiate direct oral anticoagulation than hospital-based physicians or office-based specialists. Varnier and colleagues attribute this gap to greater caution among oncology specialists managing complex patients who face higher risks of bleeding, invasive procedures, or advanced disease. General practitioners often maintain greater day-to-day familiarity with these medications because they manage a broader patient population. The study also highlighted an unexpected spike in direct oral anticoagulant use within critical care management, which researchers suspect often occurred during hospital discharge preparation rather than acute admission phases.
Frequently Asked Questions
What specific data set did the researchers examine for this analysis?
Investigators examined claims data from 683,184 patients in the French National Health Data System who experienced a first treated episode of venous thromboembolism. Among them, 91,954 patients had a diagnosis associated with cancer.
How do bleeding concerns influence treatment selection for gastrointestinal cancers?
Physicians frequently avoid direct oral anticoagulants in patients with gastrointestinal and gynecological malignancies because these tumor types are associated with concerns about bleeding risk.
What role do drug interactions play in real-world prescribing decisions?
Although potential drug-drug interactions are a key consideration in clinical practice, the French registry data showed that patient exposure to interacting drugs was not significantly associated with actual prescribing choices.